MAGEA3 and non-small cell lung carcinoma: In the MAGE‐A3 as Adjuvant Non‐Small Cell Lung Cancer Immunotherapy (MAGRIT) trial, patients which were enrolled were histologically confirmed to have resected stage IB, II, or IIIA MAGE‐A3 expressing NSCLC confirmed by polymerase chain reaction136.